1.
Korbet S, Schwartz M, Lewis E: Primary focal segmental glomerulosclerosis: Clinical course and response to therapy. Am J Kidney Dis 1994;23:773–783.
2.
Barnett HL, McNamara H, McCrory W: The effects of ACTH and cortisone on the nephrotic syndrome. Am J Dis Child 1950;80:519–520.
3.
Iitaka K, West CD: A serum inhibitor of blastogenesis in idiopathic nephrotic syndrome transferred by lymphocytes. Clin Immunol Immunopathol 1979;12:62–71.
4.
Herrod HG, Stapleton FB, Trouy RL, Roy S: Evaluation of T lymphocyte subpopulations in children with nephrotic syndrome. Clin Exp Immunol 1983;52:581–585.
5.
Matsumoto K, Osakabe K, Katayama H, Hatano M: Concanavalin A-induced suppressor cell activity in focal glomerular sclerosis. Nephron 1982;31:27–30.
6.
Arvieux J, Yssel H, Colomb MG: Antigen bound C3b and C4b enhance antigen presenting cell function in activation of human T cell clones. Immunology 1988;65:229–235.
7.
Schifferli JA, Ng YC, Peter DK: The role of complement and its receptor in the elimination of immune complexes. N Engl J Med 1986;315:488–495.
8.
Siegel I, Liu TL, Gleicher N: The red cell immune system. Lancet 1981;ii:556–559.
9.
Cornacoff JB, Hebert LA, Smead WL, Van Aman ME: Primate erythrocyte immune-complex clearing mechanism. J Clin Invest 1983;71:236–247.
10.
Kumar A, Malaviya AN, Srivastava LM: Lowered expression of C3b receptor on erythrocytes of rheumatoid arthritis patients. Immunobiology 1994;191:9–20.
11.
Fearon DT: Identification of the membrane glycoprotein that is the C3b receptor of human erythrocytes, polymorphonuclear leukocytes, B lymphocytes and monocytes. J Exp Med 1980;152:20–30.
12.
Bigi G, Monarca A, Adelasco L, Natangelo R, Croce G, Bastia A, Fiorini G: Significance of circulating C1q-binding activity in chronic liver disease: A study of 133 cases. Ric Clin Lab 1984;14:629–633.
13.
Cook JM, Kazatchkine MD, Burgeois P, Mignon F, Kahn MF: Anti-C3b receptor antibodies in patients with SLE. Clin Immunol Immunopathol 1986;38:135.
14.
Ross GD, Yount WJ, Walport MJ, Winfield JB, Parker CJ, Fuller CR, Taylor RP, Myones BL, Lachmann PJ: Disease associated loss of erythrocyte complement receptors (CR1) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. J Immunol 1985;135:2005–2014.
15.
Pascual M, Steiger G, Schifferli JA: Identification of membrane bound CR1 in human urine: Evidence for its release by glomerular podocytes. J Exp Med 1994;179:889–899.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or...
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.